Intranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice.
Khan MY, Aljehani ND, Abdulal RH, Ghazwani A, Alsulaiman RM, Eyouni M, Shebbo S, Basabrain M, Sanki MA, Alsharef AA, Abdulaal WH, Albukhari A, Qadri I, Alluhaybi KA, Altorki T, Alhabbab R, Alghanmi M, Zawawi A, Abujamel TS, Algaissi A, Thulasi Raman SN, Alfaleh MA, Alghamdi BS, Azhari AA, Li X, Mahmoud AB, Hashem AM.
Khan MY, et al.
Vaccine. 2026 Jan 1;69:127975. doi: 10.1016/j.vaccine.2025.127975. Epub 2025 Nov 12.
Vaccine. 2026.
PMID: 41232171
Free article.
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a global One Health challenge with a potential pandemic threat, with no approved vaccines or antiviral drugs available to date. Thus, there is an urgent need for a safe and effective vaccine. ...Importan …
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a global One Health challenge with a potential pandemic threat, with no appro …